ADAG vs. VSTM, CUE, CGEN, XLO, IPHA, KALV, IGMS, APLT, NGNE, and FULC
Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Verastem (VSTM), Cue Biopharma (CUE), Compugen (CGEN), Xilio Therapeutics (XLO), Innate Pharma (IPHA), KalVista Pharmaceuticals (KALV), IGM Biosciences (IGMS), Applied Therapeutics (APLT), Neurogene (NGNE), and Fulcrum Therapeutics (FULC). These companies are all part of the "medical" sector.
Verastem (NASDAQ:VSTM) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
In the previous week, Verastem had 7 more articles in the media than Adagene. MarketBeat recorded 12 mentions for Verastem and 5 mentions for Adagene. Verastem's average media sentiment score of 1.26 beat Adagene's score of -0.05 indicating that Adagene is being referred to more favorably in the news media.
88.4% of Verastem shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 2.2% of Verastem shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Verastem presently has a consensus price target of $25.69, indicating a potential upside of 548.67%. Adagene has a consensus price target of $5.00, indicating a potential upside of 78.57%. Given Adagene's higher probable upside, research analysts plainly believe Verastem is more favorable than Adagene.
Verastem has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.
Adagene has higher revenue and earnings than Verastem.
Verastem's return on equity of 0.00% beat Adagene's return on equity.
Verastem received 580 more outperform votes than Adagene when rated by MarketBeat users. However, 78.26% of users gave Adagene an outperform vote while only 65.28% of users gave Verastem an outperform vote.
Summary
Verastem and Adagene tied by winning 7 of the 14 factors compared between the two stocks.
Get Adagene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
